Avenue Therapeutics, Inc.

NasdaqCM ATXI

Avenue Therapeutics, Inc. Shareholders' Equity for the quarter ending September 30, 2024

Avenue Therapeutics, Inc. Shareholders' Equity is NA for the quarter ending September 30, 2024. Shareholders' equity are the residual interest in the assets of a company after deducting liabilities, representing the shareholders' ownership claim.

Key data

Date	Shareholders' Equity	Minority Interest	Total Equity	Total Stockholders Equity and Liabilities

NasdaqCM: ATXI

Avenue Therapeutics, Inc.

CEO	Dr. Alexandra MacLean M.D.
IPO Date	June 27, 2017
Location	United States
Headquarters	1140 Avenue of the America
Employees	3
Sector	Health Care
Industries Pharmaceuticals

Description

Avenue Therapeutics, Inc., a specialty pharmaceutical company, develops and commercializes products primarily for use in the acute/intensive care hospital setting. Its product candidate is intravenous Tramadol, a synthetic dual-acting opioid, which is in Phase III clinical trials for the treatment of post-operative acute pain. The company was incorporated in 2015 and is based in New York, New York.

Key trends

Past 5 years